Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA Plus Lactulose vs Lactulose Alone for Prevention of OHE After TIPS
NCT07273734Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ursodeoxycholic acid in hepatic encephalopathy (HE) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of Overt Hepatic Encephalopathy at 3 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT07273734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07273734.